Tasly Pharmaceutical Group Co Ltd (600535) — Capital Reinvestment Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has a Capital Reinvestment Ratio of 0.21x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥552.13 Million) in capital expenditures (CN¥117.78 Million). Check Tasly Pharmaceutical Group Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tasly Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2001–2025)
This chart tracks Tasly Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 24 annual periods. For the full cash flow conversion analysis, see 600535 cash flow metrics.
Annual Capital Reinvestment Ratio for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year Capital Reinvestment Ratio for Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. See 600535 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.27x | CN¥1.42 Billion | CN¥381.26 Million | ▼ -4.6% |
| 2024 | 0.28x | CN¥2.01 Billion | CN¥564.94 Million | ▲ +8.0% |
| 2023 | 0.26x | CN¥2.58 Billion | CN¥668.82 Million | ▲ +47.1% |
| 2022 | 0.18x | CN¥2.29 Billion | CN¥403.45 Million | ▼ -13.5% |
| 2021 | 0.20x | CN¥2.80 Billion | CN¥571.73 Million | ▼ -10.6% |
| 2020 | 0.23x | CN¥1.79 Billion | CN¥408.81 Million | ▼ -47.5% |
| 2019 | 0.43x | CN¥1.68 Billion | CN¥730.78 Million | ▼ -16.7% |
| 2018 | 0.52x | CN¥1.49 Billion | CN¥780.10 Million | ▲ +14.8% |
| 2016 | 0.45x | CN¥1.15 Billion | CN¥524.68 Million | ▼ -79.0% |
| 2015 | 2.17x | CN¥340.00 Million | CN¥737.84 Million | ▲ +77.3% |
| 2014 | 1.22x | CN¥616.76 Million | CN¥754.93 Million | ▼ -36.1% |
| 2013 | 1.92x | CN¥346.17 Million | CN¥663.56 Million | ▲ +103.1% |
| 2012 | 0.94x | CN¥413.31 Million | CN¥390.02 Million | ▼ -69.8% |
| 2011 | 3.13x | CN¥135.14 Million | CN¥422.58 Million | ▲ +643.6% |
| 2010 | 0.42x | CN¥395.05 Million | CN¥166.13 Million | ▲ +44.1% |
| 2009 | 0.29x | CN¥400.39 Million | CN¥116.80 Million | ▼ -33.7% |
| 2008 | 0.44x | CN¥260.21 Million | CN¥114.51 Million | ▼ -51.5% |
| 2007 | 0.91x | CN¥221.55 Million | CN¥201.23 Million | ▼ -50.0% |
| 2006 | 1.82x | CN¥140.56 Million | CN¥255.41 Million | ▲ +31.8% |
| 2005 | 1.38x | CN¥214.90 Million | CN¥296.33 Million | ▼ -24.2% |
| 2004 | 1.82x | CN¥203.27 Million | CN¥369.62 Million | ▼ -67.4% |
| 2003 | 5.57x | CN¥59.00 Million | CN¥328.74 Million | ▲ +811.2% |
| 2002 | 0.61x | CN¥206.22 Million | CN¥126.09 Million | ▼ -57.1% |
| 2001 | 1.42x | CN¥83.77 Million | CN¥119.35 Million | — |